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Background: Ad hoc percutaneous coronary intervention (PCI) whichwas performed immediately after diagnos-
tic catheterization has become the most common way of coronary intervention. However, limited data is avail-
able on in-hospital and long-term outcome comparing ad hoc and staged chronic total occlusion (CTO) PCI.
The aim of our study was to ﬁgure the short-term and long-term outcomes after ad hoc or staged CTO PCI.
Methods: This retrospective analysis included 512 consecutive patients that underwent 561 CTO PCI procedures
between January 2002 and December 2009. Patient basic demographics, lesion characteristics, interventional
procedure, devices used and in-hospital outcomes were compared between ad hoc and staged CTO PCI groups.
3-Year clinical outcomes that included all-cause mortality, cardiac mortality, myocardial infarction (MI), the
need for coronary artery bypass graft surgery (CABG), major adverse cardiac events (MACE) and target vessel re-
vascularization (TVR) were compared. Time-to-event analyses were performed using Kaplan–Meier statistics.
Results: Four hundred ﬁfty-one patients (80.4%) were enrolled in ad hoc CTO PCI group. Final successful revascu-
larization was higher in ad hoc CTO PCI group compared with staged CTO PCI group (82.9 vs. 77.3%, p= 0.17)
without statistical signiﬁcance. There was no signiﬁcant difference between ad hoc CTO PCI and staged CTO
PCI groups in in-hospital outcomes such as all-cause mortality, cardiac death, myocardial infarction, urgent by-
pass surgery, urgent PCI or complications. Patients with ad hoc CTO PCI had lower rate of all-cause mortality
(6.2% vs. 6.5%, p = 0.89), the need for CABG (1.9% vs. 2.1%, p = 0.89) but higher rate of cardiac mortality
(1.7% vs. 0.0%, p = 0.21), MI (1.0% vs. 0.0%, p = 0.34), MACE (24.1% vs. 17.5%, p = 0.19) and TVR (17.8% vs.
10.0%, p= 0.069) without statistical signiﬁcance in 3-year clinical outcomes.
Conclusion: 3-Year clinical outcomes compared with ad hoc CTO PCI and staged CTO PCI had insigniﬁcant differ-
ences between: all-cause mortality, cardiac mortality, MI, the need for CABG, MACE and TVR.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Percutaneous coronary intervention (PCI) for chronic total occlusion
(CTO)has become themost challenging lessons for interventional cardi-
ologists. Successful recanalization of CTO in patients with viable myo-
cardium may decrease the need for bypass surgery, reduce anginapartment of Internal Medicine,
Pei Road, Niao Sung District,
o. 40, Zihciang 2nd Rd., Cianjin
7123x2363, +886 975056407;
.
and Ltd. This is an open access articlesymptoms and improve long-term survival [1–4]. PCI instruments and
the techniques for CTO lesions had improved over time [5], and excel-
lent outcomes have been achieved in multiple pilot studies, especially
with the combined use of drug-eluting stents [4,6–8].
Ad hoc PCI, in which PCI is performed immediately after diagnostic
cardiac catheterization, has becomemore common due to the potential
advantages of cost reduction and shorter hospital stay [9–11]. However,
staged PCI indicates that PCI is performed on different days and it has
been well accepted as an alternative for complex lesions to lower the
possible risk of contrast-induced nephropathy and to increase success-
ful rate [9–11]. Although the overall mortality rates between ad hoc
and staged PCI groups were similar, some high-risk groups such as pa-
tients with congestive heart failure during admission and those who
with Canadian Cardiovascular Society class IV angina status wereunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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less likely to be performed for patients with high Syntax Score, CTO, or
complex bifurcation lesions because they are anatomically complex
[11].
The combined use of the antegrade approach and the retrograde ap-
proach hasmarkedly increased the overall success rate, however, it does
not increase the rate of major complications [12–17]. The appropriate
use of newly developed techniques and devices raises the successful
rate and brings more and more CTO into treatable category [5]. But
the appropriate strategy and timing of CTO revascularization remain
unknown.
The aim of our study was to evaluate the in-hospital and long-term
clinical outcomes between ad hoc and staged PCI for CTO in the real
world practice.
2. Materials and methods
2.1. Patient enrollment and exclusion criteria
Enrollment criteria included a documented CTO lesion which was
deﬁned as thrombolysis in myocardial infarction grade (TIMI) of 0 for
more than 3 months and the presence of typical angina or reversible
myocardial ischemia in a thallium stress study. Exclusion criteria
were: 1) a history of acute or recent stroke (b2 months), 2) acute or re-
centmyocardial infarction (MI)with unstable hemodynamic status, and
3) surgery or trauma within the preceding 2 months. The rationale of
exclusion criteria was avoiding active bleeding after anti-coagulation
during PCI and dual anti-platelet after PCI. Between January 2002 and
December 2009, a total of 561 consecutive patientswith CTO native cor-
onary vessels were collected retrospectively. The total amount of PCI
cases were 9820 patients and CTO PCI accounts for 5.7% (561/9820).
The study protocol was approved by the hospital's Internal Research
Board committee, and written informed consents including the speciﬁc
risks (such as higher complication rate and higher peri-procedure MI),
prolonged procedure and other treatment options (such as coronary ar-
tery bypass graft (CABG)) especially in multi-vessel disease of CTO in-
tervention were obtained.
2.2. Deﬁnitions
This is a single-center, single-operator registry comprised of patients
with documented CTO lesions under planned revascularization. CTO
was deﬁned as described earlier. The duration of occlusionwas estimat-
ed by the history of angina, history of myocardial infarction (MI) in the
same territory, or previous angiography. PCI indication consisted of
(1) elective; (2) urgent (required during the same hospitalization to
minimize further clinical deterioration, worsening or sudden chest
pain, congestive heart failure, acute MI, anatomy, intra-aortic balloon
pump, unstable angina with intravenous nitroglycerin, or angina at
rest); (3) emergency (to procedure or in transit to the catheterization
laboratory, ongoing ischemia despite maximal medical therapy, acute
MI ≤24 h before procedure, pulmonary edema requiring intubation,
or shock with or without circulatory support); or (4) salvage (undergo-
ing CPR en route to PCI) [18–20]. Ad hoc CTO PCI was deﬁned as PCI of
CTO vessel immediately after diagnostic cardiac catheterization. Staged
CTOPCIwas deﬁned as PCI of CTO vessel on different days after diagnos-
tic cardiac catheterization or PCI to other vessels. Multi-vessel disease
was deﬁned by stenosis of≥50% in≥2major epicardial coronary arter-
ies. The diagnostic timewasdeﬁned fromarterial puncture to diagnostic
image ﬁnished. The retrograde approach was deﬁned as the introduc-
tion of the guidewire into the collateral channels (CCs) and retrograde
success was deﬁned as guidewire successfully connected to the target
CTO vessel distal to the lesion. CTO lesion length was measured with
threemethods, from the proximal occlusion to the distal retrograde ﬁll-
ing from contralateral collaterals using a dual injection technique, start
of ﬁlling of bridging collaterals to distal vessel reconstruction, or fromthe length of the lesion visible after the guidewire crossing. Severe
calciﬁcation of a CTO lesion was deﬁned if multiple persisting
opaciﬁcations of the coronarywallwere visible inmore than oneprojec-
tion surrounding the complete lumen of the coronary artery at the site
of the lesion. Severe tortuosity was deﬁned if there were one or more
bends of 90° or more, or three or more bends of 45° to 90° proximal of
the diseased segment. Good collateral circulation was deﬁned as TIMI
3 collateral ﬂow. Contrast-induced nephropathy (CIN) was deﬁned as
an increase of baseline serum creatinine concentration of at least
0.5 mg/dl, or at least 25%, within 48 to 72 h after exposure to contrast
media. Technique success was deﬁned as successful guidewire and bal-
loon crossing with residual stenosis b50% and TIMI ﬂow grade 3. Final
procedure success was deﬁned as successful guidewire and balloon
crossing, with or without ﬁnal stenting, the presence of a ﬁnal TIMI 3
ﬂow, and a residual diameter stenosis of b30% without in-hospital
MACE.
2.3. Coronary angiogram and intravascular ultrasound
(IVUS) interpretation
Angiographic ﬁndings of the CTO lesion, CTO stumps, CTO lesion
length, collaterals, and calciﬁcation degree were assessed. All coronary
angiograms and intravascular ultrasound (IVUS) were independently
interpreted by a cardiologist who was blinded to the procedure.
2.4. In-hospital outcome
In-hospitalmajor adverse cardiac events (MACE)were deﬁned as in-
hospital death, in-hospital or peri-procedure MI (non-Q wave), or ur-
gent revascularization during the same admission. In-hospital MI was
deﬁned by elevation of cardiac troponin values N5 times the upper ref-
erence limit in patients with normal baseline values or a rise of cardiac
troponin values N20% if the baseline values are elevated as 3rd universal
deﬁnitionwith type 4b PCI relatedMI. Urgent revascularizationwas de-
ﬁned as emergency bypass surgery, or repeat PCI of the same target ves-
sel within 24 h. Cardiac death was deﬁned as death within 7 days after
MI, death associated with cardiovascular interventions within 30 days
after CABG or within 7 days after PCI. Death from uncertain causes
was also classiﬁed as cardiac death.
2.5. Endpoints
Patient were followed prospectively by telephone interview or out-
patient visit after 30 days and yearly thereafter. The following endpoints
were evaluated to compare patients between successful revasculariza-
tion versus failed revascularization, ad hoc PCI versus staged PCI: all
cause death, cardiac death, MI, the need for CABG, MACE (all cause
death, MI or target vessel revascularization (TVR)) and TVR.
2.6. Procedures and protocols
2.6.1. The decision of ad hoc CTO PCI or staged CTO PCI
The decision of ad hoc CTO PCI or staged CTO PCI was made by
operator's clinical judgments. The staged CTO PCI was considered for
the elderly and/or patients with multiple comorbidities, multiple risk
factors, poor renal function and poor ejection fraction. The staged CTO
PCI was also considered after the ad hoc CTO PCI failed. Ad hoc CTO
PCIwas frequently consideredwhenpatients presented less lesion com-
plexity, e.g. less tortuosity, less calciﬁcation, shorter lesion length, ta-
pered occlusion, and occlusion without side branch. The principles of
decisionmaking onmulti-vessel diseasewere: ﬁrst, PCI to non-CTO ves-
sel which vessel stenosis degree ≥70% then PCI to CTO vessel in staged
procedure and second, PCI to CTO vessel in ad hoc procedure without
non-CTO vessel which stenosis degree ≥70%.
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A 6-Fr Ikari IL 3.5 guiding catheter (Terumo, Tokyo, Japan) or a 6-Fr
KimnyMini-radial guiding catheter (Boston Scientiﬁc, Grove, MN, USA)
was primarily used for the antegrade approach. A 7-Fr BL 3.5–4 or AL 1–
2 short guiding catheter (Terumo) or an EBU 3.75–4 (Medtronic) was
selected speciﬁcally for every patient for the retrograde approach.
After successful engagement of both guiding catheters, a second bolus
of 5000 IU heparin was given via the catheters.
2.6.3. Bilateral simultaneous coronary injections
At least two perpendicular projections with a biplane cine-machine
were obtained, and the most proper view for the CTO intervention was
selected by using simultaneous bilateral coronary injections.
2.6.4. Selection of guidewire
The guidewire for the antegrade approach was selected by operator
after baseline coronary angiography was performed. The frequently
used guidewires ranged from those with usual stiffness as Runthrough
Floppy (Terumo, Japan), Runthrough Hypercoat (Terumo, Japan) or
Rinato wires (Asahi, Japan). Hydrophilic wires were listed such as
Pilot (Abbott, Abbott Park, IL, USA) or Fielder wires (FC or XT; Asahi,
Japan). Stiff guidewires were listed such as Miracle (3, 4.5, 6, 12 g;
Asahi, Japan), Ultimate Bros 3 (Asahi, Japan) or Conquest wires (9, 12,
or 20/8 g; Asahi, Japan). The guidewire selected was later placed at
the proximal cap of the CTO site with a 1.8-Fr microcatheter (Finecross;
Terumo). The guidewires used for the retrograde approach were
Fielder-FC, Sion, and Fielder-XT (Asahi). They were supported with a
microcatheter or an over-the-wire balloon (Ryujin 1.25 × 10 mm,
135 cm, or 150 cm; Terumo).
2.6.5. Retrograde and antegrade approaches
The retrograde approach was selected typically because of a failure
of the antegrade approach (previously or the same procedure) and/or
an unfavorable anatomy for antegradewiring. The retrograde routes in-
cluded septal channel collaterals, epicardial collaterals, saphenous vein
grafts (SVG), and the left internal mammary artery (LIMA). Collateral
selection was made with further super-selective contrast injection via
the microcatheter into the collaterals. Fielder FC or Fielder XT
guidewires (Asahi) were carefully passed through the collaterals in a
stepwise manner. After the guidewire was successfully advanced into
the distal part of the CTO vessel, retrograde wiring was attempted
with stiff wires such as with Miracle 3–6 g or Conquest-pro 9–12 g
wires and with subsequent gradually stepping-up of the wire-tip
strength. Different retrograde methods included: 1) kissing wire tech-
nique, 2) controlled antegrade and retrograde subintimal tracking
(CART) techniques, and 3) reverse CART technique or knuckle wire
technique. These techniques were used alone or in combination. After
the retrograde wire had passed the occluded segment, the retrograde
wire was manipulated into the antegrade guiding catheter, either for
balloon anchoring or for externalization of the wire, by changing the
original 190 cmwire into a 300 cm longwire through themicrocatheter
or Rendevou technique.
Stepwise balloon angioplasty was done via the antegrade or retro-
grade route, and then an antegrade soft-tip wire was advanced into
the distal portion of the occluded vessel along with the retrograde
wire, or by using a “Crusade” (Kaneka, Corp) multifunction probing
catheter. An intravascular ultrasound assessment of the occluded vessel
was performed later for the preparation of subsequent stenting. If all of
the retrograde methods failed, an antegrade approach using a stiffer
wire or the parallel-wire technique was then attempted as the last re-
sort. Rotablator was considered if the lesion could not be crossed with
the balloon or balloon popping could not be achieved. After successful
balloon dilatation, either bare-metal stent (BMS) or drug-eluting stent
(DES) was deployed based on the patient's preference. (The guideline
made by the bureau Of National Health Insurance of Taiwan reimbursesonly for BMS. The additional cost of DES has to be paid for by the
patient.)
2.6.6. Medications
Patients were pretreated with oral aspirin (100 mg/day). Pa-
tients were also pretreated with a loading dose of clopidogrel (300
or 600 mg) 4 to 12 h before the procedure. A post-procedure dose of
clopidogrel (300 mg) was administered, and then 75 mg/day was pre-
scribed for at least 9 months following implantation of DES, or at least
3 months after BMS deployment.
2.6.7. Statistical analysis
Continuous variables are reported as mean ± standard deviation,
while categorical variables are reported as frequencies. Categorical var-
iables were compared between groups by the chi-square test. Event
rates were estimated with Kaplan–Meier method. Follow-up was cen-
sored at date of last follow-up or at 3 years, whichever came ﬁrst. Sur-
vival curves with all available follow-up data were constructed for
time-to-event variables with Kaplan–Meier methodology and com-
pared by log-rank test. Data on patients who lost to follow-upwere cen-
sored at the time of last contact. A p-value of b0.05 was considered
statistically signiﬁcant. Statistical analysis was performed using SPSS
version 16.0 software (SPSS, Chicago, IL, USA).
3. Results
3.1. Population demographics
A total of 561 consecutive patients who underwent CTO revascular-
ization of either ad hoc PCI or staged PCI were collected. Among them,
451 patients were treated using ad hoc PCI and 110 patients were per-
formed with staged PCI. In staged CTO PCI group, there was 41 patients
who received adhoc CTOPCI but failed before (37.3%, 41/110). In staged
PCI group, the timing of staged PCI after initial angiogram ranges from 1
to 1002 days, and themean duration was 146.9 ± 182.6 days. The pre-
liminary results of analyses of the demographic and baseline clinical
data were summarized in Table 1, which demonstrated no signiﬁcant
difference in age, body weight, body height, and baseline creatinine
and hematocrit levels between groups. Besides, both incidences of risk
factors such as hypertension, diabetes mellitus, hyperlipidemia, and
current smoking habit and co-morbidities e.g. history of MI, CABG,
stroke, peripheral vascular disease and gastrointestinal bleeding were
similar in both groups. However, more male patients were signiﬁcantly
found in the staged PCI group (95.5% vs. 83.1%, p b 0.001). Themean left
ventricular ejection fraction, as determined by two-dimensional echo-
cardiography, was signiﬁcantly lower in the staged PCI group (52.3 ±
13.6% vs. 57.6 ± 14.6, p= 0.004).
3.2. Angiographic characteristics and measurements
The baseline angiographic characteristics of the patients collected
were summarized in Table 2, which indicated no signiﬁcant differences
in single vessel CAD ormulti-vessel CAD between groups or the location
of target lesions (e.g. LAD, RCA or LCX) between groups. The evidence of
CTO duration found that previous angiogram was more in staged PCI
group than ad hoc PCI group (29.1% vs. 13.5%, p= 0.001). The other ev-
idence of CTO such as non-invasive test, date of speciﬁc cardiac event or
unknown was similar in both groups. Non-invasive test including some
viable tests such as electrocardiography (ECG) evidence, thallium scan,
treadmill test and multi-slice computed tomography (CT) was also
listed in Table 2without signiﬁcant differences between groups. The ac-
cess site was dominantly radial artery in both groups (N80%), and a
trend of shifting from radial artery (90.9% vs. 83.6%, p= 0.074) to bra-
chial artery (4.2% vs. 9.1%, p= 0.074) or femoral artery (3.3% vs. 6.4%,
p= 0.074) was also found in both groups. The majority of the arterial
sheath sizewas both 6F but 7F arterial sheathwas usedmore frequently
Table 1
Baseline demographic characteristics in ad hoc CTO PCI group and staged CTO PCI group.
Ad hoc Staged p
(n = 451) (n = 110)
Demographics
Age, years 62.7 ± 11.2 63.7 ± 10.7 0.358
Male 375 (83.1) 105 (95.5) b0.001
Body weight, kg 69.6 ± 12.0 69.6 ± 13.1 0.981
Body height, cm 162.6 ± 8.0 162.6 ± 6.5 0.985
BSA 1.8 ± 0.2 1.8 ± 0.2 0.960
Laboratory data
Cholesterol, mg/dl 186.9 ± 54.0 181.6 ± 46.3 0.365
Triglyceride, mg/dl 166.3 ± 136.9 155.6 ± 121.4 0.475
Creatinine, mg/dl 1.4 ± 1.5 1.6 ± 1.9 0.188
eGFR 66.5 ± 26.0 63.3 ± 26.0 0.254
eGFR b60 192 (42.6) 44 (40.0) 0.767
eGFR b30 38 (8.4) 12 (10.9) 0.455
Hematocrit 39.5 ± 5.4 39.7 ± 5.6 0.684
Risk factors
Diabetes mellitus 168 (37.3) 46 (41.8) 0.383
Hypertension 315 (69.8) 82 (74.5) 0.352
Current smoker 204 (45.2) 53 (48.2) 0.595
Cholesterol N200 mg/dl 294 (65.2) 68 (61.8) 0.507
ESRD 11 (2.4) 7 (6.4) 0.062
Family history of CAD 12 (2.7) 4 (3.6) 0.582
Co-morbidity
Previous MI 140 (31.0) 36 (32.7) 0.732
Previous CABG 25 (5.5) 5 (4.5) 0.816
Previous stroke 67 (14.9) 25 (22.7) 0.061
PVD 17 (3.8) 6 (5.5) 0.423
GI bleeding 15 (3.3) 5 (4.5) 0.566
LVEF (%) 57.6 ± 14.6 52.3 ± 13.6 0.004
Data are presented as mean ± SD or number (%) of patients. CTO, chronic total occlusion;
PCI, percutaneous coronary intervention; BSA, body surface area; eGFR, estimated glomer-
ular ﬁltration rate; ESRD, end stage renal disease; CAD, coronary artery disease; MI, myo-
cardial infarction; CABG, coronary artery bypass graft; PVD, peripheral vascular disease; GI
bleeding, gastrointestinal bleeding; LVEF, left ventricle ejection fraction.
Table 2
Angiographic characteristics in ad hoc CTO PCI group and staged CTO PCI group.
Ad hoc Staged p
(n = 451) (n = 110)
CAD vessel 0.894
One vessel disease 110 (24.4) 29 (26.4)
Two vessel disease 160 (35.5) 37 (33.6)
Triple vessel disease 181 (40.1) 44 (40.0)
Target CTO vessel 0.533
LAD 180 (39.9) 38 (34.5)
LCX 76 (16.9) 22 (20.0)
RCA 195 (43.2) 50 (45.5)
Evidence of CTO 0.001
Previous angiogram 61 (13.5) 32 (29.1)
Non-invasive tests 149 (33.0) 31 (28.2)
Date of speciﬁc cardiac event 65 (14.4) 17 (15.5)
Unknown 176 (39.0) 30 (27.3)
Non-invasive tests
ECG evidence 311 (69.0) 73 (66.4) 0.647
Thallium scan 121 (26.8) 21 (19.1) 0.112
Treadmill test 65 (14.4) 12 (10.9) 0.439
Cardiac multislice CT 4 (0.9) 3 (2.7) 0.140
Access artery 0.074
Radial artery 410 (90.9) 92 (83.6)
Brachial artery 19 (4.2) 10 (9.1)
Femoral artery 15 (3.3) 7 (6.4)
Ulnar artery 7 (1.6) 1 (0.9)
Arterial sheath size b0.001
5F 2 (0.4) 0 (0.0) 0.484
6F 415 (92.0) 80 (72.7) b0.001
7F 33 (7.3) 29 (26.4) b0.001
8 F 1 (0.2) 1 (0.9) 0.278
Condition of target lesion 0.451
De novo 371 (82.3) 96 (87.3)
In-stent 63 (14.0) 11 (10.0)
PTCA restenosis 17 (3.8) 3 (2.7)
Angiographic ﬁndings
Side branch at occlusion (N1.5 mm) 164 (36.4) 44 (40.0) 0.510
Severe tortuosity 344 (76.3) 86 (78.2) 0.708
Severe calciﬁcation 140 (31.0) 41 (37.3) 0.213
Blunt occlusion 201 (44.6) 52 (47.3) 0.669
Good collaterals 276 (61.2) 72 (65.5) 0.444
Bridging collaterals 169 (37.5) 50 (45.5) 0.128
Lesion length (mm) 34.2 ± 15.0 37.3 ± 17.1 0.043
Syntax Score 20.70 ± 9.69 22.10 ± 9.73 0.179
J CTO score 2.17 ± 1.07 2.36 ± 1.15 0.114
Data are presented as mean ± SD or number (%) of patients. PCI, percutaneous coronary
intervention; CTO, chronic total occlusion; CAD, coronary artery disease; LAD, left anterior
descending artery; LCX, left circumﬂex artery; RCA, right coronary artery; ECG, electrocar-
diography; CT, computed tomography; PTCA, percutaneous transluminal coronary
angioplasty.
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tical difference, more patients were found to have de novo lesions
(87.3% vs. 82.3%) in the staged PCI group and more patients were
found to have instent total occlusion (14.0% vs. 0.9%) in the ad hoc PCI
group. The angiographic ﬁndings such as side branch at occlusion
(40.0% vs. 36.4%, p = 0.510), severe tortuosity (78.2% vs. 76.3%, p =
0.708), severe calciﬁcation (37.3% vs. 31.0, p= 0.213), blunt occlusion
(47.3% vs. 44.6%, p = 0.669), good collaterals (65.5% vs. 61.2%, p =
0.444) and bridging collaterals (45.5% vs. 37.5%, p = 0.128) were
more frequently noticed in the staged PCI group but all without statisti-
cal signiﬁcance. Lesion length was signiﬁcantly longer in the staged PCI
group (37.3 ± 17.1 vs. 34.2 ± 15.0, p= 0.043). Syntax Score and J CTO
scorewere higher in staged PCI group but without statistical differences
(22.10 ± 9.73 vs. 20.70 ± 9.69, p= 0.179; 2.36± 1.15 vs. 2.17 ± 1.07,
p= 0.114).
3.3. PCI techniques and procedure outcomes
The results of analyses of the study population regarding the inter-
ventional procedure and the procedure outcomes were also document-
ed in Table 3, which revealed no signiﬁcant differences in diagnostic
time and ﬂuoroscopic time was found between groups. However, the
procedure time was signiﬁcantly longer (113.4 ± 53.1 vs. 98.9 ± 45.3,
p= 0.005), and more contrast volumes were used (300.6 ± 145.2 vs.
275.4 ± 125.1, p = 0.051) in the staged PCI group. But, there was no
signiﬁcant difference in procedure time more than 2 h (26.8% vs.
23.6%, p= 0.547) between ad hoc PCI and staged PCI group. Our center
started retrograde approach since 2006. The trend of ad hoc PCI was not
increasing after 2006 due to retrograde approach technique mature.
In addition, signiﬁcantly more retrograde approaches (19.1% vs. 10.2%,
p = 0.014) were performed and more contralateral injection (26.4%
vs. 14.9%, p = 0.007) was offered in the staged PCI group. Retrogradesuccess rate was signiﬁcantly higher in staged PCI group (76.2% vs.
63.0%, p = 0.043) than ad hoc PCI group. The majority collaterals
were septal collaterals, epicardial collaterals, SVG and LIMA in both
groups without signiﬁcant differences. Furthermore, there was no sig-
niﬁcant difference in the use of IVUS guide, microcatheter, stiff wire
and rotablator between groups. After successful passage of guidewire,
DES (29.9% vs. 31.8%, p= 0.700), BMS (41.7% vs. 37.3%, p= 0.399), im-
plantation or ballooning (17.3% vs. 10.9%, p= 0.102) showed no signif-
icant difference between ad hoc or staged PCI. The incidences of smaller
stent diameterwhichwas deﬁned as less than 2.75mmand longer stent
length which was deﬁned as longer than 33 mmwere similar between
groups (28.4% vs. 24.5%, p = 0.581, 23.7% vs. 35.5%, p = 0.652). The
technical success was signiﬁcantly higher in ad hoc PCI group than in
the staged PCI group (89.8% vs. 82.7%, p= 0.046), but the ﬁnal proce-
dure success was insigniﬁcantly different between groups (82.9% vs.
77.3%, p= 0.170).
3.4. In-hospital outcome and complications
The preliminary results of the analyses of in-hospital outcome and
complicationswere listed in Table 4, which demonstrated no signiﬁcant
Table 3
Interventional procedure and PCI result in ad hoc CTO PCI group and stagedCTO PCI group.
Ad hoc Staged p
(n = 451) (n = 110)
Diagnostic time (min) 17.3 ± 10.6 17.6 ± 8.3 0.965
Procedure duration (min) 98.9 ± 45.3 113.4 ± 53.1 0.005
Procedure duration N2 h 121 (26.8) 26 (23.6) 0.547
Fluoroscopic time (min) 41.2 ± 24.6 44.7 ± 26.7 0.255
Contrast volume (ml) 275.4 ± 125.1 300.6 ± 145.2 0.051
Iodixanol (Visipaque) 27 (6.0) 5 (4.5) 0.653
Procedure after 2006 220 (48.8) 64 (58.2) 0.089
Retrograde approach 46 (10.2) 21 (19.1) 0.014
Retrograde success 29/46 (63.0) 16/21 (76.2) 0.043
Septal collaterals 33/46 (71.7) 15/21 (71.4) 0.099
Epical collaterals 6/46 (13.0) 4/21 (19.0) 0.112
SVG 6/46 (13.0) 2/21 (9.5) 0.658
LIMA 1/46 (2.2) 0/21 (0.0) 1.000
Contralateral injection 67 (14.9) 29 (26.4) 0.007
IVUS guide 100 (22.2) 29 (26.4) 0.377
Microcatheter use 133 (29.5) 43 (39.1) 0.066
Stiff wire use 263 (58.3) 73 (66.4) 0.130
Rotablator use 3 (0.7) 2 (1.8) 0.254
DES use 135 (29.9) 35 (31.8) 0.700
BMS use 188 (41.7) 41 (37.3) 0.399
Ballooning only 78 (17.3) 12 (10.9) 0.102
Incidence of slow ﬂow 9 (2.0) 0 (0) 1.000
Stent diameter ≤2.75 mm 128 (28.4) 27 (24.5) 0.581
Stent length ≥33 mm 107 (23.7) 39 (35.5) 0.652
Technical success 405 (89.8) 91 (82.7) 0.046
Final procedure success 374 (82.9) 85 (77.3) 0.170
Data are presented as mean ± SD or number (%) of patients. PCI, percutaneous coronary
intervention; CTO, chronic total occlusion; SVG, saphenous vein graft; LIMA, left internal
mammary artery; IVUS, intra-vascular ultrasound; DES, drug-eluting stent; BMS, bare-
metal stent.
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hospital MACE such as MI, stroke, urgent CABG, urgent PCI, cardiac
death and all-cause death (11.8% vs. 10.9%, p = 0.870) between the
patients in the ad hoc PCI and staged PCI group. In addition, the inci-
dence of complications such as perforation with or without cardiac
tamponade, side branch jailed, ventricular arrhythmia or contrast in-
duced nephropathy was higher in the staged PCI group, nevertheless
without signiﬁcant difference (12.7% vs. 7.5%, p= 0.081).
3.5. Kaplan–Meier curve for 3-year clinical outcomes
The mean follow-up duration for the study population was
4.79 years, indicating a signiﬁcantly longer duration for the ad hoc PCITable 4
In-hospital outcome and complications in ad hoc CTO PCI group and staged CTO PCI group.
Ad hoc Staged p
(n = 451) (n = 110)
Hospital stay 4.8 ± 7.3 4.3 ± 8.0 0.270
In-hospital MACE 53 (11.8) 12 (10.9) 0.870
Peri-procedure MI 29 (6.4) 6 (5.5) 0.828
Stroke 1 (0.2) 0 (0.0) 1.000
Urgent CABG 5 (1.1) 0 (0.0) 0.589
Urgent PCI 6 (1.3) 1 (0.9) 1.000
Cardiac death 2 (0.4) 0 (0.0) 1.000
All cause death 2 (0.4) 2 (1.8) 0.174
Complications 34 (7.5) 14 (12.7) 0.081
Perforation 22 (4.9) 8 (7.3) 0.343
Perforation without cardiac tamponade 19 (4.2) 8 (7.3) 0.211
Perforation with cardiac tamponade 3 (0.7) 0 (0.0) 1.000
Side branch jailed 7 (1.6) 3 (2.7) 0.420
VT/VF 5 (1.1) 3 (2.7) 0.193
CIN 22 (4.9) 6 (5.5) 0.704
Data are presented as mean ± SD or number (%) of patients. CTO, chronic total occlusion;
PCI, percutaneous coronary intervention; MACE, major adverse cardiac events; MI, myo-
cardial infarction; CABG, coronary artery bypass graft; VT/VF, ventricular tachycardia/
ventricular ﬁbrillation; CIN, contrast induced nephropathy.group (4.94 ± 2.99 vs. 4.15 ± 2.85, p= 0.007). The results of analyses
of the 3-year clinical outcomes were briefed in Table 5, showing no sig-
niﬁcant differences inMACE, all cause death, cardiac death,MI, stroke or
the need for CABG. A higher TVR was also seen in the ad hoc PCI group,
howeverwithout statistical signiﬁcance (16.4% vs. 9.1%, p= 0.054). The
3-year success rates of revascularization were shown using Kaplan–
Meier curves in Fig. 1. Patients with successful CTO revascularization
had signiﬁcant lower rates of all-cause mortality (4.5% vs. 11.1%, p =
0.0092), cardiac mortality (0.7% vs. 4.4%, p= 0.0059) and the need for
CABG (0.7% vs. 7.8%, p b 0.0001). Patients with successful CTO revascu-
larization also had lower rate of MI (0.7% vs. 1.2%, p = 0.69), MACE
(22.0 vs. 27.1%, p = 0.27) and higher rate of TVR (17.3% vs. 11.9%,
p = 0.21). But these results failed to reach statistical signiﬁcance. The
3-year clinical endpoints comparing ad hoc CTO PCI and staged CTO PCI
were shown in Fig. 2, indicating that patientswith ad hoc CTO PCI had in-
signiﬁcantly lower rate of all-cause mortality (6.2% vs. 6.5%, p = 0.89)
and theneed for CABG (1.9% vs. 2.1%, p= 0.89), but higher rate of cardiac
mortality (1.7% vs. 0.0%, p= 0.21), MI (1.0% vs. 0.0%, p= 0.34), MACE
(24.1% vs. 17.5%, p= 0.19) and TVR (17.8% vs. 10.0%, p= 0.069).
4. Discussion
The prevalence of ad hoc PCI has increased over the past decade [10,
21–25]. Several studies have suggested that ad hoc PCI is safe and effec-
tive for not only elective procedures [21,23,24] but also emergent proce-
dures [26] when compared to the staged PCI. Although immediate PCI
was not suggested for patients with complex lesions as CTOwhen diag-
nostic cardiac catheterization was performed, ad hoc CTO PCI was still
done by several interventionists [9,11]. To the best of our knowledge,
this is the ﬁrst report comparing the results of in-hospital and long-
term clinical outcomes between the ad hoc CTO PCI and staged CTO PCI.
4.1. The myth of performing CTO PCI — ad hoc or staged?
Interventional cardiologists may agree that the CTO PCI was not fre-
quently performed in our real-world practice previously for several rea-
sons. First, the successful rate of CTO intervention was not high enough
to convince patient to receive it immediately after diagnostic cardiac
catheterization was performed. Second, several newly developed de-
vices used for CTO intervention were too costly. Third, the procedure
may prolong to an unexpected duration and the following catheteriza-
tion examinations for the rest of patients may delay. Fourth, some
unexpected complicationsmay occur during CTO intervention. Most in-
terventional cardiologists choose the non-CTO lesion as theﬁrst attempt
lesion and perform the CTO lesion in the second stage because the he-
modynamic instability might be decreased when PCI was performed
in the non-CTO lesions. However, some interventional cardiologists
may select CTO lesion as the ﬁrst attempt vessel for patients withTable 5
Kaplan–Meier estimates of 3 year clinical outcomes in ad hoc CTO PCI group and staged
CTO PCI group.
Ad hoc Staged p
(n = 451) (n = 110)
Mean duration of follow-up (year) 4.94 ± 2.99 4.15 ± 2.85 0.007
Kaplan–Meier estimates of
3-year clinical outcomes
MACE 107 (23.7) 20 (18.2) 0.213
All cause death 29 (6.4) 7 (6.4) 0.980
Cardiac death 10 (2.2) 0 (0.0) 0.115
MI 4 (0.9) 0 (0.0) 0.322
Stroke 4 (0.9) 1 (0.9) 0.982
Need CABG 11 (2.4) 4 (3.6) 0.485
TVR 74 (16.4) 10 (9.1) 0.054
Data are presented as mean ± SD or number (%) of patients. CTO, chronic total occlusion;
PCI, percutaneous coronary intervention; MACE, major adverse cardiac events; MI, myo-
cardial infarction; CABG, coronary artery bypass graft; TVR, target vessel revascularization.
Fig. 1. Clinical event rates in patients who underwent successful and failed PCI of a CTO. Unadjusted Kaplan–Meier rates plotted. A. All-causemortality; B. cardiac mortality; C. myocardial
infarction; D. coronary artery bypass graft; E. major adverse cardiac events; F. target vessel revascularization.
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for CTO intervention can not only shorten procedure time but also in-
crease the success rate. Thus, the ad hoc CTO PCI becomes more and
more popular than the staged CTO PCI.4.2. Selection of ad hoc CTO PCI patients
In our study, lower creatinine level and less medical comorbidities
such as diabetes, hypertension, heavy smoker and end stage renal
disease were found in the ad hoc group, however without signiﬁcance.
Besides, insigniﬁcantly less side branch at the total occlusion site, tortu-
osity, calciﬁcation, blunted occlusion and bridging collaterals was also
found in the ad hoc group. In addition, Syntax Score and J CTO score
were higher in staged PCI group but without signiﬁcant difference. Sig-
niﬁcant differences were only seen in the lesion length and left ventric-
ular ejection fraction (LVEF) between the ad hoc CTO PCI group and
staged CTO PCI group. No deﬁnite guideline can be followed to decide
whether ad hoc CTO PCI or staged CTO PCI should be chosen. Theinterventionists would follow their own mind to achieve a successful
procedure and to prevent further complications.4.3. In-hospital clinical outcomes and complications
Clinical outcome of PCI is inﬂuenced by a large number of factors
such as baseline features, numbers and diameter of treated vessels, le-
sion length and the type and amount of implanted stents [27,28]. The in-
terventionists deny the ad hoc CTO PCI for several reasons such as
higher complication rates, higher incidence of contrast-induced ne-
phropathy and lower successful rate. On the contrary, our study re-
vealed a signiﬁcantly higher success rate in the ad hoc CTO PCI group
and insigniﬁcant rates of in-hospital MACE (all-cause mortality, cardiac
mortality, MI, urgent bypass, urgent PCI) and complications including
(perforation, ventricular arrhythmia or contrast induced nephropathy).
No association of clinical outcome and complicationswas foundnomat-
ter ad hoc CTO PCI or staged CTO PCI was performed. In our study, the
impacts between small and diffuse disease; DES and BMS were no
Fig. 2. Clinical event rates in patients who underwent ad hoc and staged PCI of a CTO. Unadjusted Kaplan–Meier rates plotted. A. All-cause mortality; B. cardiac mortality; C. myocardial
infarction; D. coronary artery bypass graft; E. major adverse cardiac events; F. target vessel revascularization.
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were similar between ad hoc CTO PCI and staged CTO PCI.
4.4. 3-Year long-term clinical outcomes
Previous reports [4] had documented that successful revasculariza-
tion of a CTO vessel is associated with reduced long-term cardiac mor-
tality and the need for coronary artery bypass graft surgery. Our study
showed the comparative result of 3-year clinical outcomes. Although
patients with ad hoc CTO PCI had slightly higher rate of cardiac mortal-
ity,MI,MACE (all-causemortality, cardiacmortality, MI, CABG and TVR)
and TVR, there was no statistical difference in the 3-year follow-up. The
reasons of higher TVR rate in ad hoc CTO PCI group compared with
staged CTO PCI may be due to less IVUS use, less retrograde approach
and less DES. We supposed that these manners of ad hoc CTO PCI may
have longer length in sub-intima space than staged CTO PCI. The reason
of higher incidence of non-cardiac death in staged CTO PCI group may
bedue to thehigher incidence of co-morbidities in these groups. Further
subgroup analysis also found that ad hoc PCI or staged PCI cannotinﬂuence the 3-year all-cause mortality. In real world practice, the all-
cause mortality was only inﬂuenced by advanced age.
4.5. Limitations
Our study has several limitations. First, there were no deﬁnite
criteria for staged or ad hoc PCI due to ethic problems in realworld prac-
tice. The cross-over detail also could not be provided. Second, the study
populationwas not randomized collected. The studymaterial was a reg-
istry data collected retrospectively from a single center. Third, the con-
tralateral injection rate and retrograde approach were relatively low
in both groups. Fourth, there was no information of cost analyses be-
tween the study groups. Fifth, the study population was small and
some of the CTO techniques and equipment were not compared.
5. Conclusions
No statistical difference was noticed for both in-hospital and long-
term clinical outcomes such as all-cause mortality, cardiac mortality,
80 H.-Y. Fang et al. / IJC Heart & Vessels 4 (2014) 73–80MI, the need of for CABG, MACE and TVR between ad hoc CTO PCI and
staged CTO PCI.
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